Danaher to acquire Aldevron for ~$9.6B gaining DNA, mRNA capabilities

  • Danaher (NYSE:DHR) has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of ~$9.6B.
  • Danaher expects to finance the acquisition using cash on hand or proceeds from the issuance of commercial paper.
  • Aldevron will operate as a standalone operating company and brand within Danaher 's Life Sciences segment.
  • Aldevron develops and custom manufactures plasmid DNA, mRNA, and proteins for research, clinical, and commercial uses.
  • Companies that operate in the same space as Danaher include Thermo Fisher Scientific (NYSE:TMO), Agilent (NYSE:A), and PerkinElmer (NYSE:PKI).
  • Rainer M. Blair, Danaher President and CEO, said, "This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster."

    Over the current book year the company from Washington could achieve a revenue around 27.74 billion USD (consensus estimates). This is hugely more than 2020's revenue of 22.28 billion USD.

    Historical revenues and results Danaher plus estimates 2020

    aandelenanalyses

    The analysts expect for 2021 a net profit of 6.62 billion USD. According to most of the analysts the company will have a profit per share for this book year of 8.87 USD. So the price/earnings-ratio equals 30.05.

    For this year the analysts expect a dividend of 80 cents per share. Thus the dividend yield equals 0.3 percent. The average dividend yield of the diversified companies equals an attractive2.07 percent.

    Danaher 's market capitalization is based on the number of outstanding shares around 185.39 billion USD. The Danaher stock was the past 12 months quite unstable. Since last June the stock is even 56 percent higher. This year the stock price moved between 169 and 271 dollar.

    Historical stock prices Danaher

    stock prices danaher

    On Friday the stock closed at 266.56 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.